Skip to main content
NewAmsterdam Pharma Co N.V. logo

NewAmsterdam Pharma Co N.V. — Investor Relations & Filings

Ticker · NAMS ISIN · NL00150012K9 LEI · 984500B6549TF6E14D36 US Professional, scientific and technical activities
Open in API
Filings indexed 374 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country NL Netherlands
Listing US NAMS

About NewAmsterdam Pharma Co N.V.

https://ir.newamsterdampharma.com/

NewAmsterdam Pharma Co N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases where currently approved treatments have not been sufficiently successful or well-tolerated. The company's lead product candidate is obicetrapib, an oral, low-dose, once-daily CETP inhibitor. It is being investigated as a therapy to lower low-density lipoprotein cholesterol (LDL-C) as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients. The company aims to address the unmet need for a potent, cost-effective, and convenient LDL-lowering treatment. In addition to its dyslipidemia program, the company also explores treatments for other metabolic disorders.

Recent filings

Filing Released Lang Actions
S-8
Regulatory Filings Classification · 92% confidence The document is a completed SEC Form S-8 registration statement under the Securities Act of 1933 for NewAmsterdam Pharma Company N.V.’s Employee Stock Purchase Plan. It is not an AGM presentation, annual report, earnings release, proxy, or financial report; rather it is a securities registration filing. There is no specific category for Form S-8 in the taxonomy, so it falls under the fallback “Regulatory Filings” (RNS).
2026-06-05 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filing reporting two items: Item 5.02 describes the adoption of an employee stock purchase plan, and Item 5.07 provides detailed vote tallies for each proposal at the June 2, 2026 Annual General Meeting. The inclusion of tabulated vote results for multiple shareholder proposals makes it a Declaration of Voting Results & Voting Rights Announcement. This matches the DVA category (“Official results from shareholder votes at any general meeting”).
2026-06-03 English
8-K - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
Regulatory Filings Classification · 85% confidence The document is a Form 8-K current report filed with the SEC, notifying investors that the company has furnished a press release (Exhibit 99.1) reporting its Q1 results. The Form 8-K does not itself include substantive financial data but simply announces and furnishes the press release. This is a general regulatory filing, so it falls under the Regulatory Filings (RNS) category rather than an Earnings Release or full financial report.
2026-05-07 English
10-Q - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
ARS - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
Annual Report
2026-05-06 English
DEF 14A - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
Proxy Solicitation & Information Statement
2026-05-06 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.